However, the mechanisms by which IFN-Is are beneficial in MS remain unclear and there is variability in the responses to IFN-β, with some MS patients showing improvement, while others having no change or worsening of disease (216, 217). The gene discussed is IFNB1; the disease is myeloid sarcoma.